Clinical Trials Browser

NETWORK × Head and Neck Neoplasms × zalutumumab × Clear all

NCT00496652 2016-11-25

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

Phase 3 Completed

Head and Neck Neoplasms